Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Consensus "Moderate Buy": Thirteen analysts cover Vor Biopharma with a consensus rating of Moderate Buy (1 sell, 4 hold, 6 buy, 2 strong buy) and an average 12‑month price target of about $50.56.
• Recent price and metrics: VOR opened at $14.33, has a market cap of $776.5M, a negative P/E (-0.04), a 52‑week range of $2.62–$65.80, and 50-/200‑day moving averages near $15.
• Insider selling amid heavy institutional ownership: Insiders sold a total of 3,002,903 shares (~$49.4M) in the last three months (including a 165,150‑share sale by Ra Capital), insiders now own 0.45% of the stock while institutions own 97.29%.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the thirteen analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation, six have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $50.5556.

Several equities research analysts recently weighed in on VOR shares. Citigroup started coverage on Vor Biopharma in a report on Friday, January 9th. They issued a "buy" rating and a $50.00 target price for the company. Wedbush boosted their target price on Vor Biopharma to $15.00 and gave the stock a "neutral" rating in a report on Tuesday, March 31st. Jefferies Financial Group started coverage on Vor Biopharma in a report on Monday, March 30th. They issued a "buy" rating and a $50.00 target price for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Vor Biopharma in a report on Wednesday, January 21st. Finally, Wells Fargo & Company started coverage on Vor Biopharma in a report on Thursday, March 19th. They issued an "overweight" rating and a $30.00 target price for the company.

Vor Biopharma Price Performance

Shares of Vor Biopharma stock opened at $14.33 on Friday. The firm has a market cap of $776.54 million, a price-to-earnings ratio of -0.04 and a beta of 1.92. Vor Biopharma has a 52-week low of $2.62 and a 52-week high of $65.80. The stock has a 50-day simple moving average of $14.98 and a 200-day simple moving average of $15.14.

Insiders Place Their Bets

In related news, Director Ra Capital Management, L.P. sold 165,150 shares of the business's stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total value of $2,604,415.50. Following the completion of the sale, the director directly owned 2,402,095 shares in the company, valued at approximately $37,881,038.15. The trade was a 6.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders sold 3,002,903 shares of company stock valued at $49,412,176. 0.45% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Vor Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. increased its position in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after buying an additional 58,247 shares during the period. Jane Street Group LLC bought a new position in Vor Biopharma in the 1st quarter worth approximately $140,000. XTX Topco Ltd bought a new position in Vor Biopharma in the 2nd quarter worth approximately $66,000. Ariose Capital Management Ltd bought a new position in Vor Biopharma in the 3rd quarter worth approximately $5,368,000. Finally, BNP Paribas Financial Markets increased its position in Vor Biopharma by 497.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company's stock worth $296,000 after buying an additional 5,058 shares during the period. 97.29% of the stock is currently owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.